Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Pyridostigmine differs from neostigmine in that:
A. It is more potent orally
B. It is longer acting
C. It produces less muscarinic side effects
D. It does not have any direct action on NM
receptors
by

1 Answer

Answer :

B. It is longer acting
by

Related questions

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Description : Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Last Answer : Ans: B

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Description : Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Last Answer : B. Rise in blood pressure

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

The cardiac muscarinic receptors: A. Are of the M1 subtype B. Are of the M2 subtype C. Are selectively blocked by pirenzepine D. Function through the PIP2 → IP3/DAG pathway

Description : The cardiac muscarinic receptors: A. Are of the M1 subtype B. Are of the M2 subtype C. Are selectively blocked by pirenzepine D. Function through the PIP2 → IP3/DAG pathway

Last Answer : B. Are of the M2 subtype

Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Description : Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Last Answer : C. Are present on vascular endothelium which has no cholinergic nerve supply

The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of acetylcholine released from motor nerve endings to a wider area activating neighbouring receptors C. Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Description : The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of ... Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Last Answer : D. All of the above

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Last Answer : Ans: A

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Neostigmine is beneficial in cobra envenomation because: A. It binds to and inactivates cobra toxin B. It reverses coma due to cobra toxin C. It counteracts the cardio-depressant action of cobra toxin D. It antagonizes the paralysing action of cobra toxin

Description : Neostigmine is beneficial in cobra envenomation because: A. It binds to and inactivates cobra toxin B. It reverses coma due to cobra toxin C. It counteracts the cardio-depressant action of cobra toxin D. It antagonizes the paralysing action of cobra toxin

Last Answer : D. It antagonizes the paralysing action of cobra toxin

Neostigmine is beneficial in cobra envenomation because: A. It binds to and inactivates cobra toxin B. It reverses coma due to cobra toxin C. It counteracts the cardio-depressant action of cobra toxin D. It antagonizes the paralysing action of cobra toxin

Description : Neostigmine is beneficial in cobra envenomation because: A. It binds to and inactivates cobra toxin B. It reverses coma due to cobra toxin C. It counteracts the cardio-depressant action of cobra toxin D. It antagonizes the paralysing action of cobra toxin

Last Answer : D. It antagonizes the paralysing action of cobra toxin

The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Description : The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Last Answer : A. They have potent antiovulatory action of their own

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Description : Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Last Answer : A. Shorter duration of action

he following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Description : Che following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Last Answer : A. It is nonselective V1 and V2 receptor agonist

Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Description : Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

The major postjunctional cholinergic receptor is of the muscarinic type at the following site: A. Postganglionic parasympathetic B. Adrenal medulla C. Autonomic ganglia D. Neuromuscular junction

Description : The major postjunctional cholinergic receptor is of the muscarinic type at the following site: A. Postganglionic parasympathetic B. Adrenal medulla C. Autonomic ganglia D. Neuromuscular junction

Last Answer : A. Postganglionic parasympathetic

The major postjunctional cholinergic receptor is of the muscarinic type at the following site: A. Postganglionic parasympathetic B. Adrenal medulla C. Autonomic ganglia D. Neuromuscular junction

Description : The major postjunctional cholinergic receptor is of the muscarinic type at the following site: A. Postganglionic parasympathetic B. Adrenal medulla C. Autonomic ganglia D. Neuromuscular junction

Last Answer : A. Postganglionic parasympathetic

riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Description : riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Last Answer : B. It has a shorter plasma half life

17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Description : 17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Last Answer : B. It has a shorter plasma half life

Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Description : Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Last Answer : D. All of the above

Reactivation of cholinesterase enzyme occurs on hydrolysis of the inhibitor by the same enzyme molecule in case of the following anticholinesterase: A. Edrophonium B. Neostigmine C. Dyflos D. Tacrine

Description : Reactivation of cholinesterase enzyme occurs on hydrolysis of the inhibitor by the same enzyme molecule in case of the following anticholinesterase: A. Edrophonium B. Neostigmine C. Dyflos D. Tacrine

Last Answer : B. Neostigmine

The following inhibitor binds only to the ani-onic site of the cholinesterase enzyme: A. Neostigmine B. Physostigmine C. Edrophonium D. Dyflos

Description : The following inhibitor binds only to the ani-onic site of the cholinesterase enzyme: A. Neostigmine B. Physostigmine C. Edrophonium D. Dyflos

Last Answer : C. Edrophonium

Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Description : Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Last Answer : D. Levobunolol

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Description : The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Last Answer : B. Dilatation of pupil

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Select the drug which is administered orally for erectile dysfunction in men: A. Yohimbine B. Papaverine C. Alprostadil D. Sildenafil

Description : Select the drug which is administered orally for erectile dysfunction in men: A. Yohimbine B. Papaverine C. Alprostadil D. Sildenafil

Last Answer : D. Sildenafil

Which of the following drugs has been used both as orally active nasal decongestant as well as appetite suppressant, and has been implicated in precipitating haemorrhagic stroke: A. Dexfenfluramine B. Phenylpropanolamine C. Isoxsuprine D. Oxymetazoline

Description : Which of the following drugs has been used both as orally active nasal decongestant as well as appetite suppressant, and has been implicated in precipitating haemorrhagic stroke: A. Dexfenfluramine B. Phenylpropanolamine C. Isoxsuprine D. Oxymetazoline

Last Answer : B. Phenylpropanolamine

Select the drug which is administered orally for erectile dysfunction in men: A. Yohimbine B. Papaverine C. Alprostadil D. Sildenafil

Description : Select the drug which is administered orally for erectile dysfunction in men: A. Yohimbine B. Papaverine C. Alprostadil D. Sildenafil

Last Answer : D. Sildenafil

Acetylcholine has no therapeutic application because: A. None of its actions are beneficial in any condition B. Its effects are transient C. It produces wide spread actions affecting many organs D. Both ‘B’ and ‘C’ are correct

Description : Acetylcholine has no therapeutic application because: A. None of its actions are beneficial in any condition B. Its effects are transient C. It produces wide spread actions affecting many organs D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Description : Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Last Answer : D. Lisinopri

Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Description : Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Last Answer : B. It hydrolyses acetylcholine at a slower rate

Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Description : Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Last Answer : B. It hydrolyses acetylcholine at a slower rate

Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Description : Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Last Answer : D. It produces prominent extrapyramidal side effect

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects